[Riluzole in amyotrophic lateral sclerosis]
Klappenbach R, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001455
Spanish
Original Title:
Riluzol para esclerosis lateral amiotrófica
Authors' recommendations:
CONCLUSIONS
Moderate quality evidence shows that riluzole increases survival in 2.3 months in patients with amyotrophic lateral sclerosis with no poor prognosis factors, and low quality evidence suggests that it would not have effects on survival in patients with poor prognosis (>75 years old, forced vital capacity 5 years). The effects of this technology on functional outcomes are contradictory. Riluzole increases mild adverse events.
The clinical practice guidelines recommend initiating treatment with riluzole in amyotrophic lateral sclerosis with good prognosis, although some guidelines state that recommendations in patients with poor prognosis are weak. Some guidelines mention treatment discontinuation criteria including occurrence of serious adverse events related to the drug or pregnancy as absolute criteria and patients under assisted ventilation or when the cost-benefit ratio is not favorable as relative criteria.
Coverage policies mentioning riluzole, including Argentina’s Mandatory Medical Program and Unique Reimbursement System, cover this health technology for amyotrophic lateral sclerosis in any prognostic group.
No cost-effectiveness studies have been found in Argentina.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Amyotrophic Lateral Sclerosis
- Riluzole
- Drug Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.